Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Maureen M O'BrienChildren's Oncology Group Study POG 9421

Abstract

To determine the outcomes, with particular attention to toxicity, of children with Down syndrome (DS) and acute myeloid leukemia (AML) treated on Pediatric Oncology Group (POG) protocol 9421. Children with DS and newly diagnosed AML (n = 57) were prospectively enrolled onto the standard-therapy arm of POG 9421 and were administered five cycles of chemotherapy, which included daunorubicin 135 mg/m(2) and mitoxantrone 80 mg/m(2). Outcomes and toxicity were evaluated prospectively and were compared with the non-DS-AML cohort (n = 565). A retrospective chart review was performed to identify adverse cardiac events. In the DS-AML group, 54 patients (94.7%) entered remission. One experienced induction failure and two died. Of the 54 who entered remission, three relapsed and six died as a result of other causes. The remission induction rate was similar in the non-DS-French-American-British (FAB) M7 (91.7%) and non-DS-non-M7 (89.3%) groups. The 5-year overall survival was significantly better in the DS-AML group (78.6%) than in the non-DS-M7 (36.3%) or the non-DS-non-M7 (51.8%) groups (P < .001). No age-related difference in 5-year, event-free survival was seen between patients younger than 2 years (75.8%) and those aged 2 to 4 years (7...Continue Reading

References

Mar 21, 1991·The New England Journal of Medicine·S E LipshultzS P Sanders
Apr 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J P KrischerS E Lipshultz
Feb 20, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K NysomS E Lipshultz
Jun 18, 1999·Archives of Disease in Childhood·J L CrazeJ M Chessells
Apr 18, 2003·Lancet·Nancy J Roizen, David Patterson
Jul 30, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alan S GamisUNKNOWN Children's Cancer Group Study 2891
Jul 13, 2004·Annals of the New York Academy of Sciences·Axel Kowald, Edda Klipp
Jun 20, 2006·Seminars in Oncology·Steven E Lipshultz
Dec 22, 2006·Pediatric Blood & Cancer·Ursula CreutzigDirk Reinhardt

❮ Previous
Next ❯

Citations

Aug 24, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·James L KalabusJavier G Blanco
Jan 12, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ching-Hon PuiRobert J Arceci
Jan 30, 2009·The Oncologist·Karen R Rabin, James A Whitlock
Jul 3, 2010·Haematologica·Ana C Xavier, Jeffrey W Taub
Dec 2, 2014·Pediatric Clinics of North America·Kelly W MaloneyParesh Vyas
Jun 19, 2014·Mitochondrial DNA. Part A. DNA Mapping, Sequencing, and Analysis·Erik HeftiJavier G Blanco
May 13, 2015·Cardiovascular Toxicology·Carrie C HoeferJavier G Blanco
Aug 5, 2016·Journal of Intellectual Disability Research : JIDR·G GloverJ Grey
Dec 11, 2014·Journal of Pediatric Hematology/oncology·Kenneth R KnechtElizabeth A Frazier
Mar 5, 2010·Paediatric Anaesthesia·Gregory J Latham, Robert S Greenberg
May 9, 2009·Journal of Oncology·Amir HarandiDamian A Laber
Nov 19, 2010·Expert Review of Hematology·Ana C XavierJeffrey Taub
Apr 25, 2012·Journal of Thyroid Research·Naifa Lamki Busaidy, Maria E Cabanillas
Aug 24, 2013·International Journal of Hepatology·Y Maor, S Malnick
Jun 26, 2014·Pediatric Blood & Cancer·J Timothy CaldwellJeffrey W Taub
Sep 19, 2014·Expert Review of Hematology·J Timothy CaldwellJeffrey W Taub
Feb 16, 2019·Journal of Immunology Research·Charles CassiusReyhan Amode
Apr 12, 2011·Pediatric Blood & Cancer·Jeffrey W Taub, Yaddanapudi Ravindranath
Feb 26, 2016·Journal of Pediatric Hematology/oncology·Erik Hefti, Javier G Blanco
Sep 19, 2017·Pediatric Blood & Cancer·Aman WadhwaAna C Xavier
Aug 22, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Diane S Krause, John D Crispino

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiomyopathy

Cardiomyopathy is a disease of the heart muscle, that can lead to muscular or electrical dysfunction of the heart. It is often an irreversible disease that is associated with a poor prognosis. There are different causes and classifications of cardiomyopathies. Here are the latest discoveries pertaining to this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.